Alumis (NASDAQ:ALMS) Major Shareholder Acquires $6,999,988.00 in Stock

Alumis Inc. (NASDAQ:ALMS) major shareholder Foresite Capital Management Vi purchased 411,764 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was bought at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the transaction, the insider directly owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. This represents a 7.78% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Foresite Capital Management Vi also recently made the following trade(s):

• On Wednesday, November 19th, Foresite Capital Management Vi purchased 190,500 shares of Alumis stock. The stock was bought at an average cost of $6.56 per share, with a total value of $1,249,680.00.
• On Tuesday, November 18th, Foresite Capital Management Vi acquired 117,374 shares of Alumis stock. The shares were bought at an average price of $6.19 per share, for a total transaction of $726,545.06.
• On Monday, November 17th, Foresite Capital Management Vi acquired 200,000 shares of Alumis stock. The shares were bought at an average cost of $5.59 per share, for a total transaction of $1,118,000.00.

Alumis Stock Up 10.1%

Shares of NASDAQ:ALMS opened at $24.34 on Thursday. Alumis Inc. has a 52-week low of $2.76 and a 52-week high of $24.83. The stock has a market cap of $2.54 billion, a P/E ratio of -6.01 and a beta of -2.09. The business has a fifty day moving average of $10.29 and a two-hundred day moving average of $6.34.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The firm had revenue of $2.07 million during the quarter, compared to analyst estimates of $3.14 million. On average, equities analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALMS has been the subject of a number of recent analyst reports. Oppenheimer restated an “outperform” rating and set a $50.00 price target on shares of Alumis in a report on Tuesday, January 6th. Wall Street Zen upgraded Alumis from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Morgan Stanley raised their target price on Alumis from $22.00 to $33.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 7th. UBS Group reaffirmed an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. Finally, Leerink Partners increased their price target on Alumis from $20.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, January 6th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Alumis presently has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Alumis News Summary

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Director Srinivas Akkaraju purchased 588,235 shares at $17.00 (~$10.0M), increasing his stake by ~46% — a material insider buy that signals management confidence. Read More.
• Positive Sentiment: Director James B. Tananbaum (and affiliated Foresite entities) bought 411,764 shares at $17.00 (~$7.0M), lifting their holdings materially — institutional/insider demand typically boosts sentiment and liquidity. Read More.
• Positive Sentiment: Major shareholder Foresite Labs/Capital increased its position (411,764 shares at $17), reinforcing institutional support and amplifying the buying pressure. Read More.
• Positive Sentiment: Market headlines cite positive plaque‑psoriasis data for lead candidate Envudeucitinib — the clinical update is a direct fundamental catalyst behind the rapid run‑up in the stock. Read More.
• Positive Sentiment: An analyst price‑target lift was reported (79.14% increase to $36.28), reflecting the same bullish re‑rating driving buy‑side interest. Read More.
• Neutral Sentiment: Several firms have reissued “outperform/buy” ratings and higher targets (MarketBeat/coverage roundup); broader analyst coverage likely magnifies volatility but also improves liquidity. Read More.
• Neutral Sentiment: Institutional ownership changes (historic buys by multiple funds) mean the stock can see larger block trades and volume swings; that can support rallies but also increases headline sensitivity. Read More.
• Negative Sentiment: Fundamental risk remains: Alumis missed most recent quarterly EPS and revenue estimates and is loss‑making — clinical execution or disappointing future readouts could quickly reverse gains. Read More.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALMS. Orbimed Advisors LLC purchased a new position in shares of Alumis during the second quarter worth $5,779,000. Velan Capital Investment Management LP purchased a new stake in shares of Alumis in the 2nd quarter valued at $4,863,000. Woodline Partners LP lifted its stake in Alumis by 809.7% during the 3rd quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock worth $6,987,000 after acquiring an additional 1,558,660 shares in the last quarter. Samsara Biocapital LLC boosted its holdings in Alumis by 47.0% during the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after acquiring an additional 1,534,872 shares during the period. Finally, Tybourne Capital Management HK Ltd. acquired a new position in Alumis in the 2nd quarter valued at about $4,198,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.